The Experts below are selected from a list of 5112 Experts worldwide ranked by ideXlab platform
Daniel O. Herzig - One of the best experts on this subject based on the ideXlab platform.
-
Surgeon leadership enables development of a colorectal cancer Biorepository
American journal of surgery, 2013Co-Authors: Vassiliki L. Tsikitis, Miriam A. Douthit, Daniel O. HerzigAbstract:Abstract Background We hypothesized that surgeons can improve the collection of all necessary elements (tissue and clinical data) needed to build a complete, robust research Biorepository. Methods All colorectal cancer patients treated at a university medical center and its affiliates were eligible for inclusion. Data were collected from an 18-page personal and family health questionnaire, a prospectively maintained clinical database, and molecular testing. Tissues included serum, plasma and peripheral blood mononuclear cells, and tumor and normal tissue. We compared 2 groups: the surgeon-referred group and the other clinician–referred group. The primary outcome was the complete collection of data (ie, preoperative/staging clinical data, blood samples, and tissue collection). Statistical analysis was performed using the Student t test. Results Since 2006, 452 patients were approached, and 430 (95%) have been enrolled. Of these, 124 were referred by their surgeon, and 306 were consented in a clinic or over the telephone. Of patients referred by their surgeon, tumor tissue, blood samples, and preoperative/staging clinical data were obtained in 119 patients; conversely, in patients referred by oncologists or other clinicians, only 133 patients had complete data (96% vs 43.5%, P Conclusions Surgeon-directed enrollment in a Biorepository improves the ability to collect blood and tissue samples. Surgeons should take a leadership role in the development of tumor biorepositories.
-
Su2094 Surgeon Leadership Enables Development of a Colorectal Cancer Biorepository
Gastroenterology, 2012Co-Authors: Miriam A. Douthit, Vassiliki L. Tsikitis, Daniel O. HerzigAbstract:BACKGROUND: We hypothesized that surgeons can improve the collection of all necessary elements (tissue and clinical data) needed to build a complete, robust research Biorepository. METHODS: All colorectal cancer patients treated at a university medical center and its affiliates were eligible for inclusion. Data were collected from an 18-page personal and family health questionnaire, a prospectively maintained clinical database, and molecular testing. Tissues included serum, plasma and peripheral blood mononuclear cells, and tumor and normal tissue. We compared 2 groups: the surgeonreferred group and the other clinician–referred group. The primary outcome was the complete collection of data (ie, preoperative/staging clinical data, blood samples, and tissue collection). Statistical analysis was performed using the Student t test. RESULTS: Since 2006, 452 patients were approached, and 430 (95%) have been enrolled. Of these, 124 were referred by their surgeon, and 306 were consented in a clinic or over the telephone. Of patients referred by their surgeon, tumor tissue, blood samples, and preoperative/staging clinical data were obtained in 119 patients; conversely, in patients referred by oncologists or other clinicians, only 133 patients had complete data (96% vs 43.5%, P ,.05). A total of 257 tissue samples were obtained from all patients. Additional testing has been performed on 228 specimens including immunohistochemistry, microsatellite testing, and genotype mutational analysis. CONCLUSIONS: Surgeon-directed enrollment in a Biorepository improves the ability to collect blood and tissue samples. Surgeons should take a leadership role in the development of tumor biorepositories.
Rowena J Dolor - One of the best experts on this subject based on the ideXlab platform.
-
The Measurement to Understand Reclassification of Disease of Cabarrus/Kannapolis (MURDOCK) Study Community Registry and Biorepository.
American journal of translational research, 2012Co-Authors: Bhattacharya S, Ashley A. Dunham, Geoffrey S. Ginsburg, Jessica D. Tenenbaum, Meredith Nahm, Marie Lynn Miranda, Robert M. Califf, Rowena J DolorAbstract:Current understanding of chronic diseases is based on crude clinical characterization, imaging studies, and laboratory testing that has evolved over decades. The Measurement to Understand Reclassification of Disease of Cabarrus/Kannapolis (MURDOCK) Study is a multi-tiered, longitudinal study designed to enable classification of chronic diseases using clinically annotated biospecimen collections, -omic technologies, electronic health records, and standard epidemiological methods. We expect that detailed molecular classification will improve mechanistic understanding of chronic diseases, augmenting discovery and testing of new treatments, and allowing refined selection of prevention and treatment strategies. The MURDOCK Study Community Registry and Biorepository will serve as a bridge for validation of initial exploratory studies, a platform for future prospective studies in targeted populations, and a resource of both data (analytical and clinical) and samples for cross-registry meta-analyses and comparative population studies. Participation of local health care providers and the Cabarrus County/Kannapolis, NC, community will facilitate future medical research and provide the opportunity to educate and inform the public about genomic research, actively engaging them in shaping the future of medical discovery and treatment of chronic diseases. We present the rationale and study design for the MURDOCK Community Registry and Biorepository and baseline characteristics of the first 6000 participants.
-
the measurement to understand reclassification of disease of cabarrus kannapolis murdock study community registry and Biorepository
American Journal of Translational Research, 2012Co-Authors: S Bhattacharya, Ashley A. Dunham, Geoffrey S. Ginsburg, Jessica D. Tenenbaum, Meredith Nahm, Marie Lynn Miranda, Robert M. Califf, M A Cornish, V A Christian, Rowena J DolorAbstract:Current understanding of chronic diseases is based on crude clinical characterization, imaging studies, and laboratory testing that has evolved over decades. The Measurement to Understand Reclassification of Disease of Cabarrus/Kannapolis (MURDOCK) Study is a multi-tiered, longitudinal study designed to enable classification of chronic diseases using clinically annotated biospecimen collections, -omic technologies, electronic health records, and standard epidemiological methods. We expect that detailed molecular classification will improve mechanistic understanding of chronic diseases, augmenting discovery and testing of new treatments, and allowing refined selection of prevention and treatment strategies. The MURDOCK Study Community Registry and Biorepository will serve as a bridge for validation of initial exploratory studies, a platform for future prospective studies in targeted populations, and a resource of both data (analytical and clinical) and samples for cross-registry meta-analyses and comparative population studies. Participation of local health care providers and the Cabarrus County/Kannapolis, NC, community will facilitate future medical research and provide the opportunity to educate and inform the public about genomic research, actively engaging them in shaping the future of medical discovery and treatment of chronic diseases. We present the rationale and study design for the MURDOCK Community Registry and Biorepository and baseline characteristics of the first 6000 participants.
Vassiliki L. Tsikitis - One of the best experts on this subject based on the ideXlab platform.
-
Surgeon leadership enables development of a colorectal cancer Biorepository
American journal of surgery, 2013Co-Authors: Vassiliki L. Tsikitis, Miriam A. Douthit, Daniel O. HerzigAbstract:Abstract Background We hypothesized that surgeons can improve the collection of all necessary elements (tissue and clinical data) needed to build a complete, robust research Biorepository. Methods All colorectal cancer patients treated at a university medical center and its affiliates were eligible for inclusion. Data were collected from an 18-page personal and family health questionnaire, a prospectively maintained clinical database, and molecular testing. Tissues included serum, plasma and peripheral blood mononuclear cells, and tumor and normal tissue. We compared 2 groups: the surgeon-referred group and the other clinician–referred group. The primary outcome was the complete collection of data (ie, preoperative/staging clinical data, blood samples, and tissue collection). Statistical analysis was performed using the Student t test. Results Since 2006, 452 patients were approached, and 430 (95%) have been enrolled. Of these, 124 were referred by their surgeon, and 306 were consented in a clinic or over the telephone. Of patients referred by their surgeon, tumor tissue, blood samples, and preoperative/staging clinical data were obtained in 119 patients; conversely, in patients referred by oncologists or other clinicians, only 133 patients had complete data (96% vs 43.5%, P Conclusions Surgeon-directed enrollment in a Biorepository improves the ability to collect blood and tissue samples. Surgeons should take a leadership role in the development of tumor biorepositories.
-
Su2094 Surgeon Leadership Enables Development of a Colorectal Cancer Biorepository
Gastroenterology, 2012Co-Authors: Miriam A. Douthit, Vassiliki L. Tsikitis, Daniel O. HerzigAbstract:BACKGROUND: We hypothesized that surgeons can improve the collection of all necessary elements (tissue and clinical data) needed to build a complete, robust research Biorepository. METHODS: All colorectal cancer patients treated at a university medical center and its affiliates were eligible for inclusion. Data were collected from an 18-page personal and family health questionnaire, a prospectively maintained clinical database, and molecular testing. Tissues included serum, plasma and peripheral blood mononuclear cells, and tumor and normal tissue. We compared 2 groups: the surgeonreferred group and the other clinician–referred group. The primary outcome was the complete collection of data (ie, preoperative/staging clinical data, blood samples, and tissue collection). Statistical analysis was performed using the Student t test. RESULTS: Since 2006, 452 patients were approached, and 430 (95%) have been enrolled. Of these, 124 were referred by their surgeon, and 306 were consented in a clinic or over the telephone. Of patients referred by their surgeon, tumor tissue, blood samples, and preoperative/staging clinical data were obtained in 119 patients; conversely, in patients referred by oncologists or other clinicians, only 133 patients had complete data (96% vs 43.5%, P ,.05). A total of 257 tissue samples were obtained from all patients. Additional testing has been performed on 228 specimens including immunohistochemistry, microsatellite testing, and genotype mutational analysis. CONCLUSIONS: Surgeon-directed enrollment in a Biorepository improves the ability to collect blood and tissue samples. Surgeons should take a leadership role in the development of tumor biorepositories.
Miriam A. Douthit - One of the best experts on this subject based on the ideXlab platform.
-
Surgeon leadership enables development of a colorectal cancer Biorepository
American journal of surgery, 2013Co-Authors: Vassiliki L. Tsikitis, Miriam A. Douthit, Daniel O. HerzigAbstract:Abstract Background We hypothesized that surgeons can improve the collection of all necessary elements (tissue and clinical data) needed to build a complete, robust research Biorepository. Methods All colorectal cancer patients treated at a university medical center and its affiliates were eligible for inclusion. Data were collected from an 18-page personal and family health questionnaire, a prospectively maintained clinical database, and molecular testing. Tissues included serum, plasma and peripheral blood mononuclear cells, and tumor and normal tissue. We compared 2 groups: the surgeon-referred group and the other clinician–referred group. The primary outcome was the complete collection of data (ie, preoperative/staging clinical data, blood samples, and tissue collection). Statistical analysis was performed using the Student t test. Results Since 2006, 452 patients were approached, and 430 (95%) have been enrolled. Of these, 124 were referred by their surgeon, and 306 were consented in a clinic or over the telephone. Of patients referred by their surgeon, tumor tissue, blood samples, and preoperative/staging clinical data were obtained in 119 patients; conversely, in patients referred by oncologists or other clinicians, only 133 patients had complete data (96% vs 43.5%, P Conclusions Surgeon-directed enrollment in a Biorepository improves the ability to collect blood and tissue samples. Surgeons should take a leadership role in the development of tumor biorepositories.
-
Su2094 Surgeon Leadership Enables Development of a Colorectal Cancer Biorepository
Gastroenterology, 2012Co-Authors: Miriam A. Douthit, Vassiliki L. Tsikitis, Daniel O. HerzigAbstract:BACKGROUND: We hypothesized that surgeons can improve the collection of all necessary elements (tissue and clinical data) needed to build a complete, robust research Biorepository. METHODS: All colorectal cancer patients treated at a university medical center and its affiliates were eligible for inclusion. Data were collected from an 18-page personal and family health questionnaire, a prospectively maintained clinical database, and molecular testing. Tissues included serum, plasma and peripheral blood mononuclear cells, and tumor and normal tissue. We compared 2 groups: the surgeonreferred group and the other clinician–referred group. The primary outcome was the complete collection of data (ie, preoperative/staging clinical data, blood samples, and tissue collection). Statistical analysis was performed using the Student t test. RESULTS: Since 2006, 452 patients were approached, and 430 (95%) have been enrolled. Of these, 124 were referred by their surgeon, and 306 were consented in a clinic or over the telephone. Of patients referred by their surgeon, tumor tissue, blood samples, and preoperative/staging clinical data were obtained in 119 patients; conversely, in patients referred by oncologists or other clinicians, only 133 patients had complete data (96% vs 43.5%, P ,.05). A total of 257 tissue samples were obtained from all patients. Additional testing has been performed on 228 specimens including immunohistochemistry, microsatellite testing, and genotype mutational analysis. CONCLUSIONS: Surgeon-directed enrollment in a Biorepository improves the ability to collect blood and tissue samples. Surgeons should take a leadership role in the development of tumor biorepositories.
Jeffrey W. Pennington - One of the best experts on this subject based on the ideXlab platform.
-
The Biorepository portal toolkit: an honest brokered, modular service oriented software tool set for biospecimen-driven translational research
BMC Genomics, 2016Co-Authors: Alex S. Felmeister, Aaron J. Masino, Tyler J. Rivera, Adam C. Resnick, Jeffrey W. PenningtonAbstract:Background High throughput molecular sequencing and increased biospecimen variety have introduced significant informatics challenges for research Biorepository infrastructures. We applied a modular system integration approach to develop an operational Biorepository management system. This method enables aggregation of the clinical, specimen and genomic data collected for Biorepository resources. Methods We introduce an electronic Honest Broker (eHB) and Biorepository Portal (BRP) open source project that, in tandem, allow for data integration while protecting patient privacy. This modular approach allows data and specimens to be associated with a Biorepository subject at any time point asynchronously. This lowers the bar to develop new research projects based on scientific merit without institutional review for a proposal. Results By facilitating the automated de-identification of specimen and associated clinical and genomic data we create a future proofed specimen set that can withstand new workflows and be connected to new associated information over time. Thus facilitating collaborative advanced genomic and tissue research. Conclusions As of Janurary of 2016 there are 23 unique protocols/patient cohorts being managed in the Biorepository Portal (BRP). There are over 4000 unique subject records in the electronic honest broker (eHB), over 30,000 specimens accessioned and 8 institutions participating in various biobanking activities using this tool kit. We specifically set out to build rich annotation of biospecimens with longitudinal clinical data; BRP/REDCap integration for multi-institutional repositories; EMR integration; further annotated specimens with genomic data specific to a domain; build application hooks for experiments at the specimen level integrated with analytic software; while protecting privacy per the Office of Civil Rights (OCR) and HIPAA.
-
The Biorepository portal toolkit: an honest brokered, modular service oriented software tool set for biospecimen-driven translational research.
BMC genomics, 2016Co-Authors: Alex S. Felmeister, Aaron J. Masino, Tyler J. Rivera, Adam C. Resnick, Jeffrey W. PenningtonAbstract:High throughput molecular sequencing and increased biospecimen variety have introduced significant informatics challenges for research Biorepository infrastructures. We applied a modular system integration approach to develop an operational Biorepository management system. This method enables aggregation of the clinical, specimen and genomic data collected for Biorepository resources. We introduce an electronic Honest Broker (eHB) and Biorepository Portal (BRP) open source project that, in tandem, allow for data integration while protecting patient privacy. This modular approach allows data and specimens to be associated with a Biorepository subject at any time point asynchronously. This lowers the bar to develop new research projects based on scientific merit without institutional review for a proposal. By facilitating the automated de-identification of specimen and associated clinical and genomic data we create a future proofed specimen set that can withstand new workflows and be connected to new associated information over time. Thus facilitating collaborative advanced genomic and tissue research. As of Janurary of 2016 there are 23 unique protocols/patient cohorts being managed in the Biorepository Portal (BRP). There are over 4000 unique subject records in the electronic honest broker (eHB), over 30,000 specimens accessioned and 8 institutions participating in various biobanking activities using this tool kit. We specifically set out to build rich annotation of biospecimens with longitudinal clinical data; BRP/REDCap integration for multi-institutional repositories; EMR integration; further annotated specimens with genomic data specific to a domain; build application hooks for experiments at the specimen level integrated with analytic software; while protecting privacy per the Office of Civil Rights (OCR) and HIPAA.
-
BIBM - Scalable biobanking: A modular electronic Honest Broker and Biorepository for integrated clinical, specimen and genomic research
2015 IEEE International Conference on Bioinformatics and Biomedicine (BIBM), 2015Co-Authors: Alex S. Felmeister, Aaron J. Masino, Tyler J. Rivera, Adam C. Resnick, Jeffrey W. PenningtonAbstract:Biorepository research has introduced significant challenges to biomedical informatics systems design and implementation. We take a best-of-breed system integrative approach to finding solutions to administer a biobank operationally, use a biobank scientifically and integrate clinical, specimen and genomic data. We introduce an electronic Honest Broker (eHB) and Biorepository Portal (BRP) open source project that, in tandem, allow for integration of data on the input and output while protecting subject privacy, a primary issue in research and healthcare informatics. Research data management systems like REDCap and our proprietary laboratory information management system (LIMS) are used as best-of-breed client systems and integrated with downstream genomic analyses. Taking this honest brokered system-client based, modular approach to Biorepository research, we allow for data and specimens to be associated with a Biorepository subject at any time point asynchronously, lowering the bar to develop new research projects based on scientific merit and having a future proofed specimen set for collaborative advanced genomic and tissue research yet to be established.
-
Scalable Biobanking: A Modular Electronic Honest Broker and Biorepository for Integrated Clinical, Specimen and Genomic Research A Data Driven and Integrative Approach to Asynchronous, Longitudinal and Collaborative Specimen and Genomic Research
2015Co-Authors: Alex S. Felmeister, Aaron J. Masino, Tyler J. Rivera, Adam C. Resnick, Jeffrey W. PenningtonAbstract:Biorepository research has introduced significant challenges to biomedical informatics systems design and implementation. We take a best-of-breed system integrative approach to finding solutions to administer a biobank operationally, use a biobank scientifically and integrate clinical, specimen and genomic data. We introduce an electronic Honest Broker (eHB) and Biorepository Portal (BRP) open source project that, in tandem, allow for integration of data on the input and output while protecting subject privacy, a primary issue in research and healthcare informatics. Research data management systems like REDCap and our proprietary laboratory information management system (LIMS) are used as best-of- breed client systems and integrated with downstream genomic analyses. Taking this honest brokered system-client based, modular approach to Biorepository research, we allow for data and specimens to be associated with a Biorepository subject at any time point asynchronously, lowering the bar to develop new research projects based on scientific merit and having a future proofed specimen set for collaborative advanced genomic and tissue research yet to be established.